PMID: 8598699Feb 10, 1996Paper

Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis

Lancet
S ten WoldeB A C Dijkmans

Abstract

A favourable benefit/risk ratio for treatment of rheumatoid arthritis (RA) with second-line drugs has been established only in short-term studies. The present investigation addresses the question of whether RA patients with a good response to long-term treatment with second-line drugs benefit from continuation of such treatment. A 52-week randomised double-blind placebo-controlled multicentre study was conducted to assess the effect of stopping second-line therapy in 285 RA patients with a good long-term therapeutic response. The patients either continued the second-line drug (n = 142) or received a placebo (n = 143). The endpoint was a flare, defined as recurrence of synovitis. At entry into the study median duration of second-line drug therapy was 5 years (range 2-33). At 52 weeks the cumulative incidence of a flare was 38% for the placebo group and 22% for the continued therapy group (p = 0.002). The risk of a flare was 2.0 times higher for patients receiving placebo than for those continuing the second-line drug (95% CI 1.27 to 3.17). The same trend was found for each second-line drug separately, with the exception of d-penicillamine. Side-effects that necessitated dose reduction or discontinuation occurred in 2 patients in...Continue Reading

References

Apr 1, 1976·Southern Medical Journal·R CadeG Spooner
Apr 1, 1992·British Journal of Rheumatology·M J WijnandsP L van Riel
Sep 1, 1992·Annals of the Rheumatic Diseases·D van ZebenF C Breedveld
Jan 1, 1988·Mayo Clinic Proceedings·S E Gabriel, H S Luthra
Mar 28, 1985·The New England Journal of Medicine·M E WeinblattD E Trentham
May 1, 1973·Arthritis and Rheumatism·M B UrowitzM A Ogryzio
Jun 1, 1984·Annals of the Rheumatic Diseases·K A Grindulis, B McConkey
Apr 1, 1984·Annals of the Rheumatic Diseases·M J AhernP J Maddison
Sep 1, 1984·Clinical Rheumatology·C E SiegertA Cats
Feb 1, 1980·Annals of the Rheumatic Diseases·R J van de Stadt, B Abbo-Tilstra
Dec 1, 1981·Arthritis and Rheumatism·N O RothermichW Bergen
Dec 1, 1981·Annals of the Rheumatic Diseases·M De Silva, B L Hazleman
Oct 1, 1981·Arthritis and Rheumatism·R S PinalsR A Larsen
Dec 1, 1994·Annals of the Rheumatic Diseases·D R PorterH A Capell
Oct 1, 1993·British Journal of Rheumatology·S M FraserH A Bird
May 12, 1994·The New England Journal of Medicine·J M Cash, J H Klippel
Feb 1, 1962·Arthritis and Rheumatism·E SCULL
Aug 11, 2010·Current Rheumatology Reports·Rania M ShammasHarold E Paulus

❮ Previous
Next ❯

Citations

Jul 24, 2010·Nature Reviews. Immunology·John D Isaacs
Feb 4, 2010·Nature Reviews. Rheumatology·Yvonne P M Goekoop-Ruiterman, Tom W J Huizinga
Aug 3, 2010·Nature Reviews. Rheumatology·Daniel Aletaha
Feb 6, 2013·Nature Reviews. Rheumatology·Maya H BuchPaul Emery
Mar 24, 2011·Current Opinion in Rheumatology·Marianne van den BroekCornelia F Allaart
Mar 24, 2011·Current Opinion in Rheumatology·Josef S Smolen, Daniel Aletaha
May 8, 2004·Annals of the Rheumatic Diseases·S M M VerstappenUNKNOWN Utrecht Rheumatoid Arthritis Cohort Study Group (SRU)
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee
Jun 24, 1998·BMJ : British Medical Journal·P Brooks
Oct 6, 2000·BMJ : British Medical Journal·R MadhokH A Capell
Aug 2, 2006·Arthritis Research & Therapy·Annette H M van der Helm-van MilTom W J Huizinga
Aug 21, 2015·Expert Review of Clinical Pharmacology·Sujith Subesinghe, Ian C Scott
Mar 1, 2009·Expert Review of Clinical Immunology·Smita AgarwalPallu Reddanna
Mar 1, 2006·Expert Review of Clinical Immunology·Benazir SaleemPaul Emery
Feb 6, 2010·Scandinavian Journal of Rheumatology·T Tiippana-KinnunenM Leirisalo-Repo
May 15, 2015·Annals of the Rheumatic Diseases·Josef S SmolenDesirée van der Heijde
Apr 16, 2015·Annals of the Rheumatic Diseases·Ronald F van VollenhovenKarin Franck-Larsson
Nov 8, 2015·Arthritis Care & Research·Jasvinder A SinghTimothy McAlindon
Jul 29, 2011·Reumatología clinica·Santos CastañedaMontserrat Corteguera
Nov 8, 2015·Arthritis & Rheumatology·Jasvinder A SinghTimothy McAlindon
Aug 25, 2010·Best Practice & Research. Clinical Rheumatology·Faye A H Cooles, John D Isaacs
Dec 25, 2015·Best Practice & Research. Clinical Rheumatology·Bruno Fautrel, Alfons A den Broeder
Apr 2, 2008·Joint, Bone, Spine : Revue Du Rhumatisme·Xavier Puéchal
Nov 17, 2005·Rheumatic Diseases Clinics of North America·Tuulikki SokkaTimo Möttönen
Jan 20, 2004·Arthritis and Rheumatism·Esmeralda T H MolenaarBen A C Dijkmans
Jul 6, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Cécile Gaujoux-VialaUNKNOWN French Society for Rheumatology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.